Henry Meds

Henry Meds has positioned itself as the premium-but-transparent option in the telehealth weight loss market. In an industry flooded with $99 Facebook-ad-driven clinics and venture-backed platforms that treat physician oversight as a regulatory checkbox, Henry Meds has staked out a different lane: charge more, but deliver a clinical experience that actually resembles medicine. Whether that premium is justified depends on what you value — and what alternatives you are comparing against.

This review is based on TriedRx's independent analysis of Henry Meds' clinical model, pharmacy sourcing, pricing structure, and aggregated patient experience data. We do not accept compensation from any vendor we review, and Henry Meds has no editorial input on this page.

Company Background

Henry Meds launched in 2021, entering the telehealth space during the post-pandemic boom that saw dozens of digital health startups race to capture demand for convenient, remote-first healthcare. Unlike many competitors that launched with a broad men's or women's health focus and later pivoted to weight loss when GLP-1 demand exploded, Henry Meds built its platform around metabolic health from the outset.

The company operates a physician-led clinical model — not a nurse-practitioner-only model, which is an important distinction in the telehealth landscape. Every initial consultation involves a licensed physician, and ongoing prescriptions require documented follow-up visits at defined intervals. This is a higher bar than many competitors meet, and it is reflected in both the clinical outcomes the platform reports and the pricing it charges.

Henry Meds is a privately held company. It has raised venture capital but has not disclosed specific funding rounds publicly at the time of this writing. The company has been transparent about its growth trajectory, claiming to have served over 100,000 patients since inception.

Product Catalog and Pricing

Henry Meds offers a focused catalog centered on GLP-1 receptor agonists for weight management:

Semaglutide Program

• Monthly cost: $297/month (includes medication, physician consultations, and shipping)
• Dosing protocol: Standard titration schedule starting at 0.25mg weekly, escalating through 0.5mg, 1.0mg, 1.7mg, and up to 2.4mg based on response and tolerability
• Supply: 30-day vials of compounded semaglutide from 503B outsourcing facilities

Tirzepatide Program

• Monthly cost: $397-497/month depending on dosing tier
• Dosing protocol: Standard titration from 2.5mg weekly, escalating through 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg
• Supply: 30-day vials of compounded tirzepatide from 503B outsourcing facilities

For context on how semaglutide works at the molecular level, see our semaglutide compound profile. For tirzepatide's dual-agonist mechanism, see our tirzepatide guide.

What the Pricing Includes

The monthly fee is all-inclusive: medication, physician consultations (initial and follow-up), metabolic screening, shipping, and ongoing care team access. There are no hidden consultation fees, separate pharmacy charges, or surprise add-ons. This bundled pricing model is a genuine differentiator — many competitors quote a low medication price but tack on $50-150 in monthly platform fees, consultation charges, or "membership" costs that inflate the real number.

That said, $297/month for compounded semaglutide is not the cheapest option available. Budget telehealth platforms offer compounded semaglutide in the $149-199 range. The question is always what you are giving up at those price points — and in most cases, it is clinical oversight depth.

Clinical Oversight Model

This is where Henry Meds genuinely earns its premium positioning. The clinical model has several features that distinguish it from the telehealth median:

Physician-led consultations: Initial evaluations are conducted by licensed physicians (MD/DO), not exclusively by nurse practitioners or physician assistants. While NPs and PAs are competent prescribers for many conditions, the obesity medicine space has enough pharmacological nuance — drug interactions, contraindications in patients with medullary thyroid carcinoma family history, pancreatitis risk stratification — that physician oversight adds meaningful safety value.

[CITATION: PubMed study needed on clinical outcomes comparison between physician-led vs NP-led GLP-1 prescribing in telehealth settings]

Structured titration protocols: Henry Meds follows evidence-based dose escalation schedules that mirror the STEP trial protocols. Patients do not jump to high doses prematurely, which is a common problem with less rigorous telehealth platforms where patients pressure providers to escalate quickly for faster results.

Metabolic screening: The onboarding process includes review of recent lab work (or ordering of baseline labs) to identify contraindications, establish metabolic baselines, and screen for conditions that might alter treatment recommendations. This is not just a liability checkbox — the platform requires specific lab values before prescribing and will decline patients who present with concerning findings.

Documented follow-ups: Follow-up consultations are not optional. They occur at structured intervals, and prescription renewals are contingent on completing them. This creates a clinical feedback loop that many telehealth competitors lack entirely.

For a deeper understanding of how semaglutide's dosing affects both efficacy and side effect profiles, see our semaglutide side effects guide.

Pharmacy Sourcing

Henry Meds sources compounded semaglutide and tirzepatide from FDA-registered 503B outsourcing facilities. This is an important regulatory distinction:

503A pharmacies compound medications on a patient-specific basis, require individual prescriptions, and operate under state pharmacy board oversight. Quality controls are generally less standardized across the 503A landscape.

503B outsourcing facilities operate under direct FDA oversight, can produce larger batches, must comply with current Good Manufacturing Practice (cGMP) requirements, and are subject to FDA inspection. The quality floor is significantly higher.

Henry Meds has been transparent about using 503B facilities, though it does not publicly name its specific compounding partners. This is common in the industry — few telehealth platforms disclose their pharmacy partners, partly for competitive reasons and partly because pharmacy relationships can change. TriedRx considers this a minor transparency gap, though not unusual for the category.

[CITATION: PubMed study needed on quality comparison between 503A and 503B compounding pharmacy outcomes for GLP-1 agonists]

The compounding pharmacy question is particularly relevant given the FDA's ongoing scrutiny of the compounded semaglutide market. The legal landscape around compounded versions of brand-name GLP-1 agonists continues to evolve, and platforms sourcing from 503B facilities are generally on stronger regulatory footing than those relying solely on 503A pharmacies.

The Onboarding Experience

The Henry Meds onboarding flow is more thorough than most telehealth competitors, which is both its strength and a potential friction point for impatient consumers:

1. Initial intake form: A detailed medical history questionnaire covering current medications, past medical history, family history (with specific attention to thyroid cancer and pancreatitis), current weight and height, weight loss goals, and prior weight loss attempts.

1. Lab review or ordering: Patients are asked to provide recent bloodwork or complete new labs. Required panels typically include comprehensive metabolic panel, lipid panel, thyroid function, and HbA1c. Some patients report that this step delays their first prescription by 3-7 days compared to competitors that skip lab requirements.

1. Physician consultation: A synchronous or asynchronous consultation with a licensed physician who reviews the intake and labs. The physician makes the prescribing decision and discusses the treatment plan, including expected timeline, side effect management, and lifestyle modifications.

1. Prescription and fulfillment: Once approved, the prescription is sent to the 503B compounding facility. Medication typically ships within 3-5 business days via cold-chain shipping.

1. Ongoing care: Follow-up check-ins at structured intervals, with the care team accessible via messaging between scheduled appointments.

Total time from sign-up to first injection typically ranges from 5-10 days, which is slower than competitors that promise medication within 48 hours but faster than traditional in-person obesity medicine pathways.

Customer Experience: What the Data Shows

TriedRx aggregates patient experience data from public forums, review platforms, social media, and community discussions. We do not rely on cherry-picked testimonials or vendor-supplied reviews.

Overall sentiment: Community reports suggest that Henry Meds patients report high satisfaction rates relative to the telehealth weight loss category. The most frequently cited positives are the quality of physician interactions, the clarity of dosing instructions, and the consistency of medication supply.

Common praise points:

• Clinical team responsiveness — based on public forum discussions, patients frequently note that care team messages receive replies within 24 hours, which is faster than many competitors
• Medication quality — community reports suggest fewer complaints about injection site reactions or potency inconsistency compared to platforms using 503A pharmacies
• Transparent billing — the all-inclusive pricing model is frequently cited as a positive, with patients noting the absence of surprise charges

Common complaints:

• Price sensitivity — $297/month is a significant recurring expense, and community sentiment indicates that some patients feel the premium over budget alternatives is difficult to justify long-term
• Onboarding speed — patients who have used faster-to-prescribe competitors sometimes express frustration with the lab requirement and multi-day onboarding process
• Cancellation process — some community reports suggest the cancellation flow could be more straightforward, though this is a common complaint across subscription telehealth platforms

Weight loss outcomes: Based on aggregated community reports, Henry Meds patients appear to track closely with the clinical trial data for compounded semaglutide — roughly 12-15% body weight loss over 6-12 months for patients who maintain treatment and adhere to dosing schedules. This is consistent with what we would expect from properly dosed, quality-controlled compounded semaglutide.

[CITATION: PubMed study needed on real-world weight loss outcomes with compounded semaglutide in telehealth settings vs clinical trial populations]

Honest Pros and Cons

What Henry Meds Does Well

• Clinical rigor above category average: The physician-led model with mandatory lab screening and structured follow-ups represents genuine clinical quality, not just regulatory compliance theater
• 503B pharmacy sourcing: Using FDA-registered outsourcing facilities rather than 503A compounding pharmacies provides a higher quality assurance floor
• Transparent all-inclusive pricing: $297/month means $297/month — no hidden fees, consultation charges, or platform subscriptions layered on top
• Structured dose titration: Following evidence-based escalation protocols reduces the risk of unnecessary side effects from overly aggressive dosing
• Care team accessibility: Messaging access to the clinical team between scheduled visits provides continuity that episodic telehealth visits do not

Where Henry Meds Falls Short

• Price premium is real: At $297-497/month, Henry Meds is 50-100% more expensive than budget telehealth competitors offering the same molecules. For patients who are confident in self-managing their treatment, the clinical premium may not feel worth it
• Pharmacy partner opacity: While 503B sourcing is disclosed, the specific compounding partners are not named publicly. Greater transparency here would strengthen trust
• Limited product catalog: Henry Meds is focused almost exclusively on GLP-1 weight management. Patients seeking broader metabolic optimization, hormone therapy, or peptide protocols need to look elsewhere
• Onboarding timeline: The 5-10 day path to first injection is slower than competitors willing to prescribe within 24-48 hours (though those faster timelines often reflect less thorough screening)
• No published third-party testing: While the company uses 503B facilities, Henry Meds has not published independent third-party testing data for its compounded medications. TriedRx would like to see COA (Certificate of Analysis) data made available

How Henry Meds Compares

In the telehealth weight loss landscape, Henry Meds occupies the upper tier for both price and clinical quality. The most relevant comparisons:

• vs. Hims: Hims offers lower pricing and faster onboarding but with less clinical depth. Hims' massive marketing budget means more brand awareness, but Henry Meds' clinical model is more rigorous.
• vs. Mochi Health: Mochi is a newer entrant with competitive pricing ($249-349/mo) and a strong clinical model. It is the closest competitor to Henry Meds in terms of clinical quality at a somewhat lower price point.
• vs. Eden: Eden targets the budget-conscious segment with pricing starting at $189/mo. The clinical oversight gap is noticeable.

For patients where clinical quality and physician oversight are the primary decision factors, Henry Meds is among the strongest options in the telehealth weight loss market. For patients where cost is the primary driver, there are less expensive alternatives — though those savings often come with compromises in clinical depth.

The GLP-1 Regulatory Landscape

Any review of a telehealth platform prescribing compounded GLP-1 agonists must acknowledge the evolving regulatory environment. The FDA has taken an increasingly active posture toward compounded semaglutide and tirzepatide, and the legal status of these compounded formulations depends on factors including drug shortage designations and individual state pharmacy law.

[CITATION: PubMed study needed on FDA regulatory actions regarding compounded GLP-1 agonists and 503B outsourcing facility compliance]

Henry Meds' use of 503B outsourcing facilities positions it more favorably within this regulatory landscape than platforms relying on 503A pharmacies, but no compounding-based telehealth platform operates with the same regulatory certainty as one prescribing brand-name Ozempic or Mounjaro. Patients should understand this context.

For a broader understanding of GLP-1 agonists as a drug class, including how different molecules compare, see our GLP-1 peptide category guide.

Who Should Consider Henry Meds

Good fit for:

• Patients who want physician-led clinical oversight, not just a prescription mill
• Patients with comorbidities (type 2 diabetes, cardiovascular disease, PCOS) who need more careful metabolic management
• Patients willing to pay a premium for an all-inclusive, structured clinical program
• First-time GLP-1 users who want thorough onboarding and structured dose titration

Less ideal for:

• Cost-sensitive patients who are comfortable with less clinical hand-holding
• Patients who want same-day or next-day prescriptions
• Patients seeking peptides beyond GLP-1 agonists (research peptides, growth hormone secretagogues, etc.)
• Patients with prior GLP-1 experience who want to self-direct their dosing

TriedRx Verdict

Henry Meds earns an 8.9/10 and an A- grade because it delivers on its core promise: a clinically rigorous, transparently priced telehealth weight loss program with genuine physician oversight and quality pharmacy sourcing. The premium pricing is the primary reason it does not reach an A — for many patients, the clinical delta between Henry Meds and a competent mid-tier platform does not justify the $100-150/month price difference.

That said, in a market where many platforms treat clinical oversight as an inconvenience to be minimized rather than a value to be delivered, Henry Meds stands out. If you are going to spend $300+ per month on a weight loss program, this is the category of clinical experience you should expect.

Frequently Asked Questions

Is Henry Meds legit?

Yes. Henry Meds is a licensed telehealth platform that uses physician-led consultations and sources medications from FDA-registered 503B outsourcing facilities. It is not a prescription mill — the onboarding process includes medical history review, lab screening, and structured physician consultations before any prescriptions are issued.

How much does Henry Meds cost per month?

Henry Meds charges $297/month for its semaglutide program and $397-497/month for tirzepatide, depending on dosing tier. These prices are all-inclusive — medication, physician consultations, metabolic screening, and shipping are bundled with no hidden fees.

Does Henry Meds require lab work?

Yes. Henry Meds requires recent bloodwork (or will order baseline labs) before prescribing GLP-1 medications. Required panels typically include comprehensive metabolic panel, lipid panel, thyroid function, and HbA1c. This adds 3-7 days to the onboarding timeline compared to platforms that skip lab requirements.

Where does Henry Meds source its medications?

Henry Meds sources compounded semaglutide and tirzepatide from FDA-registered 503B outsourcing facilities, which operate under direct FDA oversight and must comply with current Good Manufacturing Practice (cGMP) requirements. The specific pharmacy partners are not publicly disclosed.

How long does it take to get medication from Henry Meds?

Total time from sign-up to receiving your first injection typically ranges from 5-10 days. This includes completing the intake form, lab review, physician consultation, prescription processing, and cold-chain shipping. This is slower than some competitors but reflects a more thorough screening process.

Can I cancel Henry Meds at any time?

Henry Meds operates on a monthly subscription basis. Cancellation is available, though some community reports suggest the process could be more streamlined. Contact customer support directly to initiate cancellation and confirm any applicable billing cycle details.

Is compounded semaglutide from Henry Meds the same as Ozempic?

Compounded semaglutide contains the same active molecule as brand-name Ozempic and Wegovy but is produced by compounding pharmacies rather than Novo Nordisk. It is not FDA-approved as a finished product in the same way brand-name versions are. Henry Meds uses 503B facilities that operate under FDA oversight, but compounded medications inherently carry different quality assurance profiles than manufactured brand-name drugs.

What side effects should I expect with Henry Meds' semaglutide?

The most common side effects mirror those documented in clinical trials: nausea (especially during dose escalation), constipation, diarrhea, and injection site reactions. Henry Meds' structured titration protocol — starting at low doses and escalating gradually — is designed to minimize these effects. See our semaglutide side effects guide for comprehensive coverage.

This review was last updated on April 13, 2026. TriedRx reviews are independent and uncompensated. If you represent Henry Meds and believe any information here is inaccurate, contact our editorial team for correction consideration.